Kornimate/medical-research-clean huggingface dataset:
value of ct-scan and oral gastrografin in the management of post operative small bowel obstruction

Conditions: Small Bowel Obstruction

Summary: small bowel obstructions are responsible for 2 to 5% of emergency hospital admissions and 20% of all emergency surgical procedures. in 60 to 80% of cases, acute small bowel obstructions are the consequence of intraperitoneal postoperative adhesions. they constitute an extremely frequent pathology, leading to a high rate of hospital admissions and money expense. management of small bowel obstruction is based on 2 options: either a surgical approach where all patients are operating on, or a conservative treatment in which surgery is proposed in case of failure of medical treatment. the surgical approach leads to operate on an excessive rate of patients while the medical approach increases the risk of increased small bowel resection, morbidity rate or hospitalization duration. in order to improve the management of small bowel obstruction, it seems necessary to better distinguish patients that need an emergency surgical procedure from patients in which medical treatment will be useful. many studies have been performed to investigate the value of imaging in the management of small bowel obstruction, using abdominal x-ray, oral gastrografin administration or ct-scan. the aim of this study is to analyse the effect of a systematic performance of imaging investigation on the management of patients presenting with a postoperative small bowel obstruction. all patients suffering from a postoperative small bowel obstruction will be included in this study. they will be randomised in 2 groups. in group s, patients will have ct-scan and oral water administration while in group sg, patients will have ct-scan and oral gastrografin administration the major end point of this study is to analyse whether imaging examination can reduce the need for a surgical approach or the rate of small bowel resection and to determine its influence on fasting time or hospitalization duration


Eligibility criteria:
inclusion criteria: * small bowel obstruction in patients with previous abdominal surgery exclusion criteria: * age less than 18 years * early small bowel obstruction (less than 4 weeks following abdominal surgery) * small bowel obstruction in the course of digestive cancer. * hyperthermic small bowel obstruction * small bowel ischemia (fever, peritoneal signs, increased leucocytosis) * pregnancy ( elevated béta hcg levels) * inflammatory bowel disease * previous abdominal radiotherapy * pneumoperitoneum * colorectal obstruction
intravenous injection of adipose derived mesenchymal stem cell for als

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is a lethal degenerative disorder that upper motor and lower motor neurons are destroyed in brain stem and spinal cord. riluzole is the only therapeutic option now. recently several studies have shown that stem cell transplantation is safe and can be effective in reduction of disease progression and increase of quality of life.

the study is perform with 8 patients who has sporadic form of als with(als-functional rating test) als-frs\> 24 and (forced vital capacity) fvc\>40% . the adipose sample is provide from healthy donors with abdominal lipoaspiration. after isolation and culture of mesenchymal stem cells, the cells are injected intravenously (2 million cells/kg). all the patients will be followed for 12 months at 72hours, 2months, 4 months, 6 months and 12 months after transplantation to find the adverse events. during follow up the assessments including: als-frs, fvc and electromyography and serologic tests.

Eligibility criteria:
inclusion criteria: * both gender * age: 18-55 * sporadic form of disease * als-frs\> = 24 * fvc \>= 40% exclusion criteria: * familial form of als * malignancy * autoimmune disease * diagnosis of other motor neuron diseases

Keywords: adipose tissue mesenchymal stem cell intravenous injection als
respiratory alterations of acid-base equilibrium: acute and chronic renal response

Conditions: Acute Respiratory Variations of Acid-base Equilibrium

Summary: alterations of acid-base equilibrium are very common in critically ill patients. thus, understanding their pathophysiology and the possible compensatory mechanisms acting in different organs may play an important role in better set the consequent clinical treatment. the lung and the kidney are the two principal actors of such regulations. although the respiratory response to acid-base alterations is well understood, less information are available for what the renal system is concerned. such lack of information is partially due to: 1) the historical consideration of the kidney as a "slow" organ, in response to variations in acid-base equilibrium; 2) the lack of a monitoring system to closely assess renal response. our group has recently developed a monitoring system aimed at analyzing, in a quasi-continuous and non-invasive manner (every 10 min) the urinary profile in terms of urinary ph and electrolyte concentrations (sodium, potassium, chloride, ammonium). the investigators hypothesize that the renal system reacts to large as well as to minimal variations of the acid-base equilibrium (especially induced by a variation in the respiratory function) in a very fast way, modifying the urinary concentration (and therefore the urinary excretion) of ammonium and some electrolytes (especially chloride).

primary aim: to investigate the acute renal response to respiratory alterations of acid-base equilibrium in order to better understand the underlying physiological mechanisms and to evaluate the validity of a renal monitoring system to indirectly assess the effectiveness of the respiratory function. secondary aim: to collect data on the chronic response of the renal system in patients affected by chronic obstructive pulmonary disease (copd), as well as on the acute response to acute variation of the chronic respiratory acidosis characterizing patients affected by copd exacerbation. study protol: mechanically ventilated patients will undergo controlled variation of the ventilatory setting (hyperventilation vs. hypoventilation) in order to induce a controlled reduction or increase in arterial partial pressure of carbon dioxide (and an increase or reduction of arterial ph), within normal range of ph (7.35 - 7.45) during the variations, urinary concentrations of electrolytes and ph will be monitored.

Eligibility criteria:
inclusion criteria: 1. presence of mechanical ventilation 2. presence of arterial and central venous line 3. presence of urinary catheter exclusion criteria: 1. acute or chronic renal failure with anuria 2. presence of continuous renal replacement therapy 3. hemodynamic instability 4. less than 16 years of age

Keywords: acid-base equilibrium renal system urinary electrolytes
al-15469a for the treatment of bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: the purpose of the study is to determine whether al-15469a is safe and effective in the treatment of bacterial conjunctivitis.


Eligibility criteria:
inclusion criteria: * signs \& symptoms of conjunctivitis exclusion criteria: * under 1 mo. age
improving nutrition and health outcomes in intibuca, honduras

Conditions: Malnutrition; Undernutrition

Summary: the purpose of this research study is to better understand how to prevent malnutrition in children under age 5 years in intibuca, honduras. a randomized community trial design was used to implement a nutrition program, including a complementary nutrition supplement, educational sessions, and growth and health monitoring integrated into the basic primary care package, to participants living in communities in the intervention group. participants living in the control group communities will receive the nutrition supplement for one year following the study.


Eligibility criteria:
inclusion criteria: * children between the ages of 6 months and under 5 years at the time enrollment who reside in concepcion. exclusion criteria: * children with congenital anomalies, mental retardation, severe physical handicap, undernutrition caused by medical conditions that contribute to undernutrition such as heart disease, kidney failure, face and throat problems that interfere with swallowing, medical problems interfering with the absorption of food, and chronic diseases such as tuberculosis, etc. * plans to move or change place of residence outside the intervention region in the next 2 months. * children whose weight for age z score falls below - 3. * children whose weight for age z score is above 3.
hvpg-guided therapy versus evl plus nsbb in second prophylaxis of esophageal variceal bleeding

Conditions: Esophageal Varices in Cirrhosis of the Liver

Summary: a single-center randomized controlled study comparing endoscopic or interventional therapy guided by the hepatic venous pressure gradient (hvpg) , to standard endosopic variceal ligation plus nonselective beta-blocker therapy (nsbb) in patients with esophageal varices due to liver cirrhosis with a history of esophageal variceal hemorrhage.primary study outcome of the study is variceal rebleeding episodes occurring within the first years after interventions. second study outcomes of the study are hepatic encephalopathy occurrence, mortality occurrence, liver transplantation or other cirrhosis-related complications.


Eligibility criteria:
inclusion criteria: * liver cirrhosis diagnosed by clinical examination, imaging or biopsy; * a previous history of variceal hemorrhage; * written informed consent. exclusion criteria: * previous history of secondary prophylactic treatment; * contraindications to treatment of endoscopy, surgery and tips * severe cardiac, pulmonary or renal dysfunction; * lactating or pregnant; * malignancies;
glucose control during labour in gestational diabetes mellitus with insulin treatment: a randomized controlled trial

Conditions: Gestational Diabetes; Hypoglycemia, Neonatal

Summary: pregnant women with gestational diabetes who are treated with insulin and their daily insulin dose is 30 iu or more will be randomized into two groups. active treatment group will receive insulin-glucose-infusion during labour. in the observational group, blood glucose level during labour will be monitored and insulin-glucose-infusion is started only if needed. the hypothesis is that there will not be a difference in rate of hypoglycemia between the two groups and that the proportion of observational group participants that need infusion is low.

intrapartum blood glucose level has negative correlation to neonatal blood glucose level in type 1 diabetics. in gestational diabetes the correlation is less clear. in the view of current knowledge, it seems that moderately elevated intrapartum blood glucose may not cause neonatal hypoglycemia. there is no consensus of how to treat intrapartum blood glucose level in gestational diabetics. some studies have implied that most of mothers with gestational diabetes would have normal blood glucose level during labour and hence would not need any intervention if their daily insulin dosage is less than 0,5-1 iu/kg. study participants are recruited into the study at tampere university hospital maternity ward when their daily insulin dose exceeds 30 iu. randomization is done at 37th gestational week, if vaginal delivery is planned, and hba1c is measured. randomization envelope is opened at the delivery ward when active labour begins and treatment of blood glucose level is carried out accordingly. if insulin dose is 1 iu/kg or more, the participant is treated as in active treatment group despite of result of randomization. all neonates will receive milk substitute after birth in labour ward. plasma glucose is measured immediately if neonate has symptoms of low blood sugar. if not, plasma glucose is measured approximately two hours after birth and after that every 4 hours until plasma glucose is 3,0 mmol/l or more in three consecutive measurements.

Eligibility criteria:
inclusion criteria: * pregnant women with gestational diabetes mellitus and daily insulin dosage of 30 iu or more exclusion criteria: * planned caesarean section, * premature birth (\< 37 gestational weeks)
correlation of protection against varicella in an exploratory study

Conditions: Varicella

Summary: this study consists of two parts. part 1 is a retrospective cohort study and part 2 is a prospective cohort study. in part 1 ,the scaled logit model was used to assess the correlation between varicella-zoster virus (vzv) antibody titers using fluorescent-antibody-to-membrane-antigen assay (fama) 30 days after varicella vaccine immunization and the risk of subsequent varicella breakout/disease , to determine the protective threshold for achieving fama antibodies. part 2 was to validate the model in part 1.

part 1 was based on a previous phase ⅲ, randomized, placebo-controlled clinical trial (nct02981836) conducted from 2016 to 2017. the analysis data of part 1 was from historical serum, historical varicella cases and additional one year case monitoring conducted as an extension of the phase iii study. part 2 was conducted based on close contacts of varicella cases. all close contacts without varicella symptoms will be recruited and followed up for 14 days to monitor the occurrence of the varicella cases. part 2 aimed to compare the differences of fama antibody titers in varicella breakthrough cases, non-breakthrough cases, and non-cases at the time of exposure to validate/calibrate the model established in part 1.

Eligibility criteria:
inclusion criteria: * 1-12 years children who were the siblings or children of the indicator varicella cases, or the deskmates/roommates of the indicator varicella cases; * having close contacts with the indicator varicella cases at least 2 days during the period from 5 days before the onset and 2 days after the onset; * without varicella vaccination history or having varicella vaccination history (the last dose of varicella was manufacured by sinovac, with an interval of \>30 days before enrollment) * subjects/legal guardian can understand and sign the informed consent; * being able to provide legal proof of identity. exclusion criteria: * without varicella history; * body temperature ≥37.0℃ on the day of enrollment, or skin rash on the head, torso, and limbs; * having any confirmed or suspected immunodeficiency disorder, including tumor patients undergoing chemotherapy, human immunodeficiency virus (hiv) infection, continuous use of steroid hormones for more than 30 days (prednisone equivalent ≥2mg/kg days in children), or having other immunosuppressive disorder as determined by the clinician; * the investigators considered that participation in this study was not appropriate for various other reasons.
regional anesthesia for modified radical mastectomy with axillary lymph node dissection

Conditions: Breast Cancer

Summary: local and regional anesthesia have been introduced with the goal of reducing the side effects associated with general anesthesia and iv opioid analgesia.our hypothesis is that ultrasound-guided interscalene brachial plexus block and erector spinae plane block will provide efficient surgical anesthesia and postoperative analgesia after modified radical mastectomy.

inadequate analgesia after modified radical mastectomy with axillary lymph node dissection may occur with most of regional anesthesia. pain in the axilla and upper limb is related to ineffective block of medial and lateral pectoral nerves as long thoracic and thoracodorsal nerves, leading to inadequate analgesia.the aim of this study is to evaluate the efficacy and safety of ultrasound-guided interscalene brachial plexus block and erector spinae plane block for providing surgical anesthesia and postoperative analgesia after modified radical mastectomy.

Eligibility criteria:
inclusion criteria: * female patients aged 40-85 years old * american society of anesthesiologists' physical status iii and iv * planned for modified radical mastectomy with axillary lymph node dissection exclusion criteria: * patient refusal * neurological or psychiatric disorders * local infection at injection site * spine or chest wall deformity * allergy or any contraindication to any of the study drugs * opioid or alcoholic addiction * chronic pain of any cause * uncooperative patients.
an open-label extended clinical protocol of ranibizumab to evaluate safety and efficacy in rare vegf driven ocular diseases.

Conditions: Choroidal Neovascularization; Macular Edema; Glaucoma, Neovascular; Diabetic Retinopathy

Summary: the pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare vegf driven ocular diseases.


Eligibility criteria:
inclusion criteria: * active choroidal neovascularization (cnv) * active macular edema (me) * rubeosis iridis/neovascular glaucoma. * proliferative diabetic retinopathy requiring vitrectomy. exclusion criteria: * wet age-related macular degeneration * pathologic myopia * pseudoxanthoma elasticum * diabetic macular edema * retinal vein occlusion * \< 18 years of age * history of hypersensitivity to ranibizumab * use of any systemic anti-angiogenic drugs 3 months before inclusion * women of child-bearing potential and pregnant or nursing (lactating) women. * active or suspected ocular infection
the pioneer-01 study of the imagio breast imaging system

Conditions: Breast Cancer

Summary: this is a prospective controlled multi-center study involving gray scale (b-mode) ultrasound vs oa/us (opto-acoustic and gray scale ultrasound) for the visualization of suspicious masses. imagio gray scale and oa image sets will be collected on each enrolled mass and pushed to an imaging core lab for processing and then to a set of independent readers who will read the imagio gray-scale images vs the imagio oa/us images.

imagio is a multi-modality device, comprised of one probe with the ability to image with diagnostic gray scale (b mode) ultrasound alone and gray scale in conjunction with oa together in a six up image.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * suspicious mass of breast, identified by a health care practitioner within the past 30 days with diagnostic methodology other than conventional ultrasound. exclusion criteria: * presence of a condition or impediment that may interfere with imaging. * pregnant or lactating * undergoing neoadjuvant therapy

Keywords: breast imaging diagnosis breast ultrasound imagio seno medical instruments, inc. seno opto-acoustics oa angiogenesis blood map
zephyr etude post-inscription (french registry)

Conditions: Emphysema or COPD

Summary: the objective of this registry is to provide ongoing safety and effectiveness assessment of the zephyr valve treatment of adult patients with chronic obstructive pulmonary disease (copd) grade iii and grade iv in order to support the renewal of the inscription of the zephyr valve on the list lppr (art 165-1) in france.

this is a multi-center, single-arm, prospective registry to be conducted at a minimum of 12 study centers. approximately 150 patients with severe emphysema undergoing zephyr valve treatment will be enrolled and followed out to 3 years. assessments will be performed at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure. patients prescribed the zephyr valve treatment will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. safety and effectiveness of the zephyr valve treatment will be evaluated post-treatment based on data collected out to 3-years post-treatment.

Eligibility criteria:
inclusion criteria: * patients with emphysema (copd grade iii and grade iv) considered appropriate for the bronchoscopic lung volume reduction procedure by the physician. * subjects who signed an informed consent form to allow data collection. exclusion criteria: * subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).
spo2 accuracy of noninvasive disposable pulse oximeter sensor with motion conditions

Conditions: Healthy; Hypoxia

Summary: the purpose of this clinical study is to validate the spo2 accuracy of the stryker sustainability solutions pulse oximetry sensors during motion conditions over the range of 70-100% sao2 as compared to arterial blood samples assessed by co-oximetry. the end goal is to provide supporting documentation for the spo2 accuracy validation of the reprocessed sensors.

in this study, the level of oxygen within the blood will be reduced in a controlled manner by reducing the concentration of oxygen the participant breathes. the accuracy of a noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation measurements from a laboratory blood gas analyzer. it is required that the accuracy root mean square (arms) performance of the stryker pulse oximetry sensors will meet a specification of +/-3% or better in motion conditions for the range of 70 - 100% sao2 (typically, saturation is determined once with air breathing and then at one of 6 levels, e.g. 94%, 90%, 85%, 80%, 75% and 70% saturation for about 30-60 seconds at each level), thereby demonstrating an acceptable spo2 accuracy performance specification. motion is defined as controlled rubbing or tapping of the subject's fingers in a 2-4 hz or random sine motion with 2-3 cm amplitude.

Eligibility criteria:
inclusion criteria: * good general health with no evidence of pre-existing medical problems * fluent in both written and spoken english * must be able to review informed consent and is willing to comply with study procedures exclusion criteria: * obesity (bmi \>30) * known history of heart disease, lung disease, kidney or liver disease * prior diagnosis of asthma, sleep apnea, or use of cpap * diabetes * clotting disorder * hemoglobinopathy or history of anemia that in the opinion of the investigators would make them unsuitable for study participation * any serious systemic illness * current smoker * any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigator would interfere with the sensors working correctly * history of fainting or vasovagal response * history of sensitivity to local anesthesia * prior diagnosis of raynaud's disease * unacceptable collateral circulation based on exam by investigators (allen's test) * pregnant, lactating, or trying to get pregnant * unable or unwilling to provide informed consent, or unable or unwilling to comply with study procedures * any other condition which in the opinion of the investigators would make them unsuitable for the study
terlipression prevent developing of acute kidney injury during upper-gastroentestinal bleeding

Conditions: Cirrhosis, Liver; Upper Gastrointestinal Bleeding

Summary: the investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.

54 cirrhotic patients with uppre-gastrointestinal bleeding were entrolled and were distributed into terlipressin group and control group at 1:1 rate. patients in terlipressin group received 1mg/6h of terlipressin intravenously for 5 days, and patients in control group recerved 1mg/12h of somatostatin intravenously for 5 days. at enrollment, 24h,48h,72,and 1week, the renal function index level( serum creatinine,urine biochemistry and urinary tubule injury index etc) were tested.

Eligibility criteria:
inclusion criteria: * diagnosied as cirrhosis with upper gastrointestinal bleeding 18≤age≤70 varicose vein rupture occurred within 24 hours, without drug, endoscopy or interventional therapy can read, understand and sign informed consent exclusion criteria: * pregnant women, lactating women; serious cardiovascular disease: history of acute cardiac infarction, heart block, heart failure, arterial hypertension(（sbp\>170mmhg and/ or dbp\>100mmhg） occlusive lower extremity venous disease asthma, chronic obstructive pulmonary disease have serious or unable to control other organ diseases; cerebrovascular disease; age ≥70 years old known to be allergic to therapeutic drugs chronic kidney disease weight ≤40kg

Keywords: liver cirrhosis upper gastrointestinal bleeding acute kidney injury urinary il-18